322.2 - Pharmacogenetics of Kinases and Its Impact on the Activation of Nucleotide Reverse Transcriptase Inhibitor Prodrugs
Monday, April 4, 2022
3:32 PM – 3:55 PM
Room: 113 C - Pennsylvania Convention Center
Introduction: This session will discuss how genetic variants and tissue-specific expression of drug-metabolizing enzymes could affect the activation, pharmacokinetics, and therapeutic efficacy of various prodrugs with a focus on antiviral and anticancer medications. The session will stimulate the discussion regarding how to use genetic variants and tissue-specific proteomics information of drug-metabolizing enzymes to improve the design and delivery of prodrugs and enhance the efficacy and safety of prodrug pharmacotherapy.
